Specialty Pharma Journal Specialty, Precision & Technology
SAN DIEGO–(BUSINESS WIRE)–Retrophin, Inc. (NASDAQ:RTRX) today announced the closing of the agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sanofi (EURONEXT: SAN and NYSE: SNY). Under the terms of the agreement, Retrophin has received a payment of $150 million, and will receive two additional payments of $47.5 …
Tag Archives: FDA Voucher
July, 2015
May, 2015
-
27 May
Sanofi Pays $245 Million for Retrophin’s Priority Review Voucher
Retrophin, Inc. has sold its priority review voucher to Sanofi for $245 million in cash. In March, Retrophin bought small drugmaker, Asklepion Pharmaceuticals, for roughly $75 million, gaining Cholbam (cholic acid), a drug approved by the US Food and Drug Administration (FDA). Retrophin has already gained that $75 million back …
March, 2015
-
18 March
With FDA’s Approval of Cholbam, Retrophin Gains Rare Disease Drug and Voucher
Orphan drug biotech Retrophin saw its shares go up nearly 30 percent today, after news hit that not only was the company’s rare disease drug approved, but that it also received a priority review voucher from US health regulators. Today, the US Food and Drug Administration (FDA) approved Cholbam (cholic …